{"disease":{"id":"marginal-zone-lymphoma-mzl","name":"marginal zone lymphoma mzl"},"drugs":{"marketed":[{"drug_id":"zanubrutinib","indication_name":"Marginal zone lymphoma (MZL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brukinsa","generic_name":"ZANUBRUTINIB","company_name":"BeiGene","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"allr3","indication_name":"Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03869619","title":"REal World Data in LYmphoma and Survival in Adults","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06149286","title":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07173790","title":"Watch and Wait or Worry and Wait in Indolent Lymphoma","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":250,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT07208981","title":"Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":169,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06793189","title":"MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":145,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03265158","title":"Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0","phase":"","overall_status":"UNKNOWN","enrollment_count":108,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT06782854","title":"Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the \"Off the Beaten Track\" Liquid Biopsy","phase":"","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06700798","title":"Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Fei Li","has_results":false},{"nct_id":"NCT07355699","title":"Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":88,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT03547115","title":"A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":84,"lead_sponsor_name":"MEI Pharma, Inc.","has_results":false},{"nct_id":"NCT03846427","title":"Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT07480863","title":"Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07022223","title":"Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07299331","title":"Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Zhengzhou University","has_results":false},{"nct_id":"NCT07448324","title":"Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07247383","title":"Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":39,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07372365","title":"Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":23,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04450069","title":"CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT04488354","title":"Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Calibr, a division of Scripps Research","has_results":false},{"nct_id":"NCT05720052","title":"A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"MingSight Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT04796922","title":"To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Incyte Corporation","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}